Zydus Lifesciences Gets Clean USFDA Report for Ahmedabad Unit
ECONOMY & POLICY

Zydus Lifesciences Gets Clean USFDA Report for Ahmedabad Unit

Zydus Lifesciences Ltd has received a clean report from the US Food and Drug Administration (USFDA) for its manufacturing facility at SEZ-II in Ahmedabad, the company informed in a stock exchange filing on Wednesday, 5 November.

The Pre-Approval Inspection (PAI) was conducted between 11 and 14 August 2025 and concluded without any observations. Following the inspection, the USFDA issued an Establishment Inspection Report (EIR), classifying the site as “No Action Indicated” (NAI) — effectively closing the inspection.

Zydus stated that the outcome reaffirms its strong compliance standards and enhances its regulatory track record, paving the way for future product approvals from the facility. The disclosure was made in line with Regulation 30 of SEBI’s Listing Obligations and Disclosure Requirements (LODR).

The company also announced that its Board of Directors will meet on 6 November to consider a proposal to raise up to Rs 50 billion through the issue of eligible securities. The fundraising options may include a qualified institutional placement (QIP), rights issue, preferential allotment, or private placement.

Additionally, the board will consider initiating a postal ballot process to seek shareholder approval for the proposed fundraising. The company is also scheduled to announce its July–September quarter results on the same day.

In the first quarter of FY26, Zydus reported a 3.3 per cent rise in net profit to Rs 14.67 billion, supported by a foreign exchange gain of Rs 570 million. Revenue for the quarter grew 6 per cent year-on-year to Rs 65.74 billion, while EBITDA remained flat at Rs 20.89 billion. Profit margins stood at 31.8 per cent, compared with 33.6 per cent a year earlier.

The clean USFDA report is expected to further strengthen Zydus Lifesciences’ regulatory credibility and growth prospects in the US pharmaceutical market.

Zydus Lifesciences Ltd has received a clean report from the US Food and Drug Administration (USFDA) for its manufacturing facility at SEZ-II in Ahmedabad, the company informed in a stock exchange filing on Wednesday, 5 November. The Pre-Approval Inspection (PAI) was conducted between 11 and 14 August 2025 and concluded without any observations. Following the inspection, the USFDA issued an Establishment Inspection Report (EIR), classifying the site as “No Action Indicated” (NAI) — effectively closing the inspection. Zydus stated that the outcome reaffirms its strong compliance standards and enhances its regulatory track record, paving the way for future product approvals from the facility. The disclosure was made in line with Regulation 30 of SEBI’s Listing Obligations and Disclosure Requirements (LODR). The company also announced that its Board of Directors will meet on 6 November to consider a proposal to raise up to Rs 50 billion through the issue of eligible securities. The fundraising options may include a qualified institutional placement (QIP), rights issue, preferential allotment, or private placement. Additionally, the board will consider initiating a postal ballot process to seek shareholder approval for the proposed fundraising. The company is also scheduled to announce its July–September quarter results on the same day. In the first quarter of FY26, Zydus reported a 3.3 per cent rise in net profit to Rs 14.67 billion, supported by a foreign exchange gain of Rs 570 million. Revenue for the quarter grew 6 per cent year-on-year to Rs 65.74 billion, while EBITDA remained flat at Rs 20.89 billion. Profit margins stood at 31.8 per cent, compared with 33.6 per cent a year earlier. The clean USFDA report is expected to further strengthen Zydus Lifesciences’ regulatory credibility and growth prospects in the US pharmaceutical market.

Related Stories

Gold Stories

Next Story
Real Estate

Anshul Singhal launches Vantrock with Rs 42 billion development plan

Real estate professional Anshul Singhal has launched Vantrock Real Assets Private Limited (VRAPL), a Mumbai-headquartered platform focused initially on warehousing, industrial and logistics parks. The company plans to develop approximately 11.5 million sq ft of assets, with an estimated gross development value (GDV) of Rs 42 billion (approximately USD 434 million) on completion.The first phase will cover around 3 million sq ft across the National Capital Region (NCR), Bengaluru and Pune, with an estimated development value of Rs 11 billion (approximately USD 113 million). Construction is sched..

Next Story
Infrastructure Transport

Afcons wins CII award for biodiversity management

Afcons Infrastructure has received the Confederation of Indian Industry (CII) National Award for Environmental Best Practices 2026 in the Biodiversity Management category for its work on the Mumbai-Ahmedabad High Speed Rail Project’s C-2 package.The award was presented at a ceremony in Chennai on 9 October 2026. It was received by Mihir Mishra, Vice-President, CPE, and Sumon Paul, Assistant General Manager, HSE, along with the Afcons team.The project adopted several resource recovery and waste management practices. These included recycling concrete washout waste to recover sand, aggregates a..

Next Story
Technology

Indian businesses lead globally in planned AI investment, says Autodesk

Indian organisations are moving towards deeper integration of artificial intelligence (AI), digital technologies and sustainability into business operations, according to Autodesk’s 2026 State of Design & Make report. The fourth edition of the annual study highlights growing AI adoption, measurable outcomes from digital transformation and the role of sustainability in long-term business growth.The report found that 64 per cent of Indian organisations are approaching or have achieved their current AI goals. While 88 per cent believe AI will enhance their industry, up from 78 per cent in 2..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

SPECIAL OFFER
QR Code